Refine your search
656 results found
DLA Piper | USA | 18 Jun 2019
Major developments in class action litigation for 2018 - 2019
The relationship between class actions and arbitration remains a hot issue at the Supreme Court, where the trend in favor of arbitration continues…
Faegre Drinker Biddle & Reath LLP | USA | 29 May 2019
Federal Courts Continue to Split Over Whether They Have Personal Jurisdiction Over Claims Brought By Non-Forum Class Members Against Non-Forum Defendants
For years, the plaintiffs’ bar has crammed thousands of non-forum class members into a single action in order to more easily justify broader…
Matheson | European Union, Ireland, OECD, etc. | 19 Feb 2019
Life Sciences Update: Outlook for 2019 and Post-Brexit Implications
2019 has started with a flurry of large M&A deals in the Life Sciences sector. In early days of January global pharmaceutical giant Bristol-Myers…
Troutman Pepper | USA | 8 Feb 2019
Sometimes the Patent Office Has the Last and Only Word
The Federal Circuit just issued a decision that confirms its stance on Article III standing for appeals from inter partes reviews (IPRs), making it…
Harness, Dickey & Pierce, PLC | USA | 7 Feb 2019
Abandoning Infringing Conduct Caused Loss of Standing to Appeal IPR
In Momenta Pharmaceuticals, Inc. v. Bristol-Myers Squibb Co., [2017-1694] (February 7, 2019), the Federal Circuit dismissed the appeal of the PTAB’s…
Davies Collison Cave | Singapore | 21 Dec 2018
When and how can a Singapore patent application be corrected?
The above question arose in the case of Novartis (Singapore) Pte Ltd v Bristol-Myers Squibb Pharma Co [2017] SGHC 322. This is the first time the…
Womble Bond Dickinson (US) LLP | USA | 2 Nov 2018
Splitting Hairs?: Court Finds Bristol-Myers Squibb Does Not Apply to Rule 23 Class Actions and Denies Motion to Dismiss Claims of Non-Resident Class Members in Nationwide TCPA Class Action
A few weeks ago, Judge Leigh Martin May in the Northern District of Georgia denied a Defendant’s Rule 12(b)(2) motion to dismiss brought on the basis…
Dechert LLP | USA | 31 Oct 2018
Delaware Found to be Improper Venue for ANDA Suit
The District of Delaware dismissed a Hatch-Waxman Act ANDA lawsuit that Bristol-Myers Squibb had filed against Mylan Pharmaceuticals, finding that…
Spruson & Ferguson | Global | 29 Oct 2018
Pat-INFORMED: A powerful new searching tool, but don’t be left Part-INFORMED
A new database has been launched with the principal purpose of providing easily accessible and understandable information about the patent status of…
Troutman Pepper | USA | 25 Oct 2018
Only Half the Story: Material Distinctions Determine Dismissal of Claims Against Non-Residents Under Bristol-Myers
Last week, the U.S. District Court for the Middle District of Florida rejected a Defendant’s attempt to dismiss a proposed class action claiming Fair…
